Referanser

  1. WHO. Diabetes. Fact sheet http://www.who.int/mediacentre/factsheets/fs312/en/2017 [cited 2017 22.august].
  2. Hallan SI, Coresh J, Astor BC et al. Internasional comparison of the relationship of chronic kidney disease prevalence and ESRD risk. Journal of the American Society of Nephrology: JASN. 2006;17(8):2275-84.
  3. Strøm H, Engeland A, Eriksen E et al. Hvor mange og hvem behandles medikamentelt for diabetes mellitus? Tidsskr Nor Legeforen. 2006;6(126):768-70.
  4. Upublisert data fra HUNT database. Personlig meddelelse. Overlege dr.med. Stein Hallan; St Olavs Hospital, Trondheim
  5. Intensive blood-glucose control with sulphonylureas or insulin compared with convenGonal treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England). 1998;352(9131):837-53.
  6. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
  7. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.
    2008;358(24):2560-72.
  8. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med.
    2009;360(2):129-39.
  9. Moen MF, Zhan M, Hsu VD et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clinical journal of the American Society of Nephrology : CJASN. 2009;4(6):1121-7.
  10. Finske guidelines til behandling av T2DM http://www.terveysportti.fi/xmedia/ccs/varhainen_diabetes_en.html [cited 2017 29.august].
  11. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a paGent-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2012;35(6):1364-79.
  12. Helsedirektoratet. Nasjonal faglig retningslinje for diabetes (internet) https://helsedirektoratet.no/retningslinjer/diabetes2016 [cited 2017
    22.august].
  13. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes care. 2005;28(12):2948-61.
  14. Coca SG, Ismail-Beigi F, Haq N et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Archives of internal medicine. 2012;172(10):761-9.
  15. Thomas MC, Paldánius PM, Ayyagari R et al. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy. 2016;7(3):439-54.
  16. Scirica BM, BhaV DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med.
    2013;369(14):1317-26.
  17. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus 2012 [cited 2017 22.august].
  18. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247-57.
  19. Marso SP, Daniels GH, Brown-Frandsen K et al. LiragluGde and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016.
  20. Ferrannini E, Solini A. SGLT2 inhibiGon in diabetes mellitus: raGonale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502.
  21. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57.
  22. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
  23. Hallan SI, Øvrehus MA, Romundstad S et al. Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway. Kidney InternaGonal. 2016;90(3):665-73.
  24. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.
    2004;351(13):1296-305.
  25. Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Internal Medicine Journal. 2004;34(1-2):50-7.
  26. GuGerrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the “trade-off” hypothesis.
    Clinical journal of the American Society of Nephrology : CJASN. 2010;5(9):1710-6.
  27. O’Hare AM, Choi AI, Bertenthal D et al. Age affects outcomes in chronic kidney disease. Journal of the American Society of Nephrology : JASN.
    2007;18(10):2758-65.

Kontakt info

  • sadollah.abedini@siv.no

Om oss

Denne hjemmeside er en uavhengig portal som har til hensikt å formidle veiledning om optimal omsorg av pasienter med kronisk nyresykdom i primærhelsetjenesten. Vi håper den kan medvirke til bedre henvisningspraksis, behandling og oppfølging av kronisk nyresykdom

Meny